Accurate identification of substrates of a protease is critical in defining its physiological functions. We previously predicted that Dsg-2 (desmoglein-2), a desmosomal protein, is a candidate substrate of the transmembrane serine protease matriptase. The present study is an experimental validation of this prediction. As demanded by our published method PNSAS [Prediction of Natural Substrates from Artificial Substrate of Proteases; Venkatraman, Balakrishnan, Rao, Hooda and Pol (2009) PLoS ONE 4, e5700], this enzyme-substrate pair shares a common subcellular distribution and the predicted cleavage site is accessible to the protease. Matriptase knock-down cells showed enhanced immunoreactive Dsg-2 at the cell surface and formed larger cell clusters. When matriptase was mobilized from intracellular storage deposits to the cell surface there was a decrease in the band intensity of Dsg-2 in the plasma membrane fractions with a concomitant accumulation of a cleaved product in the conditioned medium. The exogenous addition of pure active recombinant matriptase decreased the surface levels of immunoreactive Dsg-2, whereas the levels of CD44 and Ecadherin were unaltered. Dsg-2 with a mutation at the predicted cleavage site is resistant to cleavage by matriptase. Thus Dsg-2 seems to be a functionally relevant physiological substrate of matriptase. Since breakdown of cell-cell contact is the first major event in invasion, this reciprocal relationship is likely to have a profound role in cancers of epithelial origin. Our algorithm has the potential to become an integral tool for discovering new protease-substrate pairs.
INTRODUCTION
Proteases play a central role in cellular homoeostasis and are responsible for the spatio-temporal regulation of function. Many putative proteases have been identified through genomic approaches leading to a surge in global profiling attempts to characterize their natural substrates [1a] . In order to complement the ongoing efforts to identify physiologically relevant substrates of proteases and assess their cellular functions under normal and pathological conditions, we had proposed a novel prediction strategy [1] . We used sequence information from experimentally proven substrates of endoproteases and incorporated dual filters to identify the most probable candidates. These filters imposed a strong quantitative rule to assess the accessibility of a potential cleavage site and a qualitative co-localization rule which would ensure their likelihood of interaction. By using these criteria we catalogued potential substrates of serine proteases from the PDB and UniProt databases. Identity of the substrates was used for functional annotation to reveal novel functions of the proteases [1] . We have developed a web-based server for users to identify such cleavage sites on their query substrate (http://www. actrec.gov.in/pi-webpages/Prasanna/index.htm).
Matriptase is a type II serine protease found in the membrane of epithelial cells [2] . Under physiological conditions, matriptase plays a crucial role in hair follicle development by processing profilaggrin to filaggrin monomers [3] . The matriptase-prostatin cascade, with matriptase acting upstream of prostatin, has been found to be crucial in epithelial differentiation [4] . Matriptase also plays a crucial role in regulating the survival of developing T-lymphocytes in the thymic microenvironment [5] . Through its action on substrates like pro-HGF (hepatocyte growth factor)/SF-1 (scatter factor 1) and pro-uPA (urokinase-type plasminogen activator) [6] [7] [8] [9] , matriptase is likely to impart invasive properties to cancer cells. A potential association between matriptase deregulation and Ras-mediated carcinogenesis has been reported [10] .
Matriptase is overexpressed in many cancer tissues [11, 12] , such as primary breast carcinomas [13, 14] , ovarian tumours of epithelial origin [15] [16] [17] and prostate cancer [18] . Clinicopathological correlation between expression levels of matriptase and different grades of these tumours suggest that matriptase could be a good biomarker for the diagnosis and treatment of malignant breast tumours, a favourable prognostic marker in ovarian cancer and in staging of human prostate adenocarcinoma [14] [15] [16] [17] [18] . In vitro inhibition of matriptase prevented the growth of prostate and colon carcinoma cell lines with invasive properties [19] . Thus a strong correlation exists between matriptase and cellinvasive properties. In addition matriptase seems to possess strong tumorigenic potential. However, the mechanism by which matriptase mediates invasion remains unclear. Identification of novel substrates would help in correlating changes in expression levels, activity and the observed phenotype. Previously, using our method called PNSAS (Prediction of Natural Substrates from Artificial Substrate of Proteases) [1] , we had identified Dsg-2 (desmoglein-2) as a novel putative substrate of matriptase. Dsg-2 is a desmosomal protein which harbours a putative cleavage site for matriptase, LGR∼S (P3P2P1∼P1 ), between residues number 565 and 566.
Desmosomes are intercellular junctions that confer strong cell-cell adhesion properties. They are found in epithelia and cardiac muscles and are located at the cell membrane, where they act as anchors for intermediate filaments. The core of the desmosomal adhesive complex primarily consists of the desmogleins (Dsg1-4) and desmocollins (Dsc1-3). These glycoproteins belong to the cadherin superfamily of proteins. A decrease in the levels of the desmosomal proteins desmoplakin and plakophilin-1 in oral cancer tissues and a decrease in desmoplakin in breast cancer tissues in relation to normal tissues emphasizes the importance of these cell junction proteins in disease progression and metastasis. This may be also true of other tumour types, like adenocarcinoma and oral squamous cell carcinomas [20] [21] [22] [23] [24] . One of the mechanisms by which early stage tumour cells acquire an invasive phenotype is by undergoing EMT (epithelial-mesenchymal transition). This is accompanied by secretion of proteases, which together results in disruption of adherent junctions and desmosomal integrity, enabling cancer cells to dissociate from the primary tumour site and invade the surrounding tissues [21] . Dsg-2 was reported to be a substrate of kallikerin-7, a chymotryptic-like serine protease, in pancreatic cancer cells [25] .
Therefore the unique ability of tumour cells to invade and metastasize can be attributed to a fundamental deregulation between its pro-adhesion components and the proteases that degrade the ECM (extracellular matrix) and break cell-cell contact [26] . Since Dsg-2 is responsible for cell-cell adhesion and matriptase is an enzyme implicated in cell invasion, we asked if Dsg-2 would be a relevant physiological substrate of matriptase. In the present study we show that Dsg-2 is indeed a physiologically relevant substrate of matriptase. Reciprocal levels of the enzyme and its cognate substrate at the cell surface results in altering the cell adhesion properties of HCT-116 cells, implying a role for matriptase in cell invasion through its novel substrate Dsg-2.
MATERIALS AND METHODS

Chemicals and reagents
Formaldehyde solution was obtained from Merck (catalogue number 61783705001046). S1P (sphingosine 1-phosphate) (catalogue number S9666) was purchased from Sigma. S1P was prepared at 10 μg/ml in HPLC-grade methanol and final working solution was prepared at 50 ng/ml. BSA (catalogue number A7906), IPTG (isopropyl β-D-thiogalactopyranoside; catalogue number I6758) and mitomycin C (catalogue number M0503) were procured from Sigma. Ampicillin (catalogue number RM 645) was obtained from Himedia.
Cell culture conditions
Experiments were conducted on the human colonic carcinoma cell line HCT-116 wt (wild-type; a gift from Dr Sorab Dalal, ACTREC, Navi Mumbai, India) and HEK (human embryonic kidney)-293 cells. These cells were cultured in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10 % FBS (fetal bovine serum), 1.5 g/l sodium bicarbonate and 1 % antibiotic/antimycotic solution containing streptomycin, amphotericin B and penicillin.
Antibodies
Monoclonal anti-Dsg-2 antibody clone 6D8 and AH12.2 (recognizing the extracellular domain) were purchased from Invitrogen (catalogue number 32-6100) and Santa Cruz Biotechnology (catalogue number sc-80663) respectively. Rabbit anti-(human matriptase) antibody, which recognizes the extracellular protease domain (residues 800-855), was obtained from Bethyl laboratories (catalogue number A300-221A). Secondary HRP (horseradish peroxidase)-labelled anti-mouse (NA931) and antirabbit (NA934) antibodies were procured from GE Healthcare. Primary rat monoclonal anti-CD44 antibody, Alexa Fluor TM 488-conjugated sheep anti-(rat IgG) antibody and anti-rat HRPlabelled secondary antibodies were gifts from Dr Rajiv Kalraiya (ACTREC, Navi Mumbai, India) and primary monoclonal anti-E-cadherin antibody was a gift from Dr Sorab Dalal.
Total cell lysate preparation and subcellular fractionation
Cells from 95 % confluent dishes of HCT-116 wt cells were trypsinized and washed twice with 1× PBS. Pellets were suspended in lysis buffer [50 mM Tris (pH 7.5), 125 mM NaCl and 0.5 % Nonidet P40 with 1× cocktail of protease inhibitors], briefly vortex-mixed and incubated on ice for 30 min. Cell suspension was then centrifuged at 15 000 rev./min (Plastocraft Rota 4R rotor) for 15 min at 4
• C. The supernatant was collected and stored at − 20
• C. A Subcellular Protein Fractionation kit (78840) by Pierce and Thermo Scientific were used for preparing membrane and cytosolic fractions. The amount of protein in the cell lysates was estimated by the Bradford method using BSA as standard.
SDS/PAGE and Western blotting
Cell lysates were mixed with 1× Lammelli's sample buffer under non-boiling conditions and proteins were separated by SDS/PAGE (10 % gel). To detect Dsg-2, samples were boiled for 5 min followed by SDS/PAGE (7.5 % gel). The proteins were transferred on to PVDF membranes overnight at 4
• C (Bradford wet-transfer blotting apparatus set at 70 V and 200 mA). Unbound sites were blocked using 3 % BSA in TBST [Tris-buffered saline containing 0.05 % Tween 20 (pH 7.4)] for 2 h. Incubation with primary antibody for matriptase (1:250 dilution) and Dsg-2 AH12.2 clone (1:250 dilution) was performed for 2 h at room temperature (25 • C). Secondary antibodies against matriptase (1:5000 dilution) and Dsg-2 (1:2500 dilution) were incubated for 1 h at room temperature. Each incubation step was followed by six washes, each for 10 min, with TBST. The blots were developed using the ECL (enhanced chemiluminescence) Plus kit (GE Healthcare RPN2132) on Kodak X-ray films.
Detection of shed ectodomain of Dsg-2 in the conditioned medium of HCT-116 wt cells
One million HCT-116 cells were seeded in six 90-mm dishes and allowed to grow until they reached 98 % confluence. The growth medium from confluent monolayers was removed and cells were subjected to overnight serum starvation. Cells were washed twice with 1× PBS and incubated in a serum-free medium containing 50 ng/ml S1P for 2 h at 37
• C. Post-incubation, the conditioned media were collected, pooled and centrifuged at 400 g for 5 min at 4
• C and then concentrated using Amicon Ultra-4 centrifugal filter units, 10 kDa nominal molecular mass limit (Millipore), according to the manufacturer's instructions.
To detect shed Dsg-2, equal concentrations of control and S1P-treated conditioned medium were mixed with Lammelli's buffer and immunoblotted as described above. Primary Dsg-2 AH12.2 clone (1:250 dilution) was incubated for 2 h at room temperature followed by anti-mouse-HRP (1:2500 dilution) for 1 h at room temperature.
Immunofluorescence microscopy
Cells were seeded on to autoclaved coverslips and grown to confluence. For the S1P-based experiments, cells were subjected to overnight serum starvation followed by incubation with 50 ng/ml S1P for 2 h. For the siRNA (small interfering RNA)-mediated matriptase down-regulation, cells were treated with 50 nM of siRNA against matriptase with 2.5 μl/ml of transfection reagent. Cells were incubated for 24 h and then the siRNAcontaining medium was replaced by normal complete medium. The cells were allowed to proliferate for another 24 h and fixed (see below). To study the effect of exogenously added purified recombinant matriptase, HCT-116 wt cells were incubated with 5 or 10 μg/ml of proteolytically active matriptase (constituted in incomplete DMEM adjusted to pH 8.8) for 2 h at 37
• C. For immunostaining, cells were fixed and permeabilized (3.7 % formaldehyde for 20 min at room temperature and 0.05 % Triton X-100 for 10 min at room temperature respectively). BSA (3 %) was used to block non-specific sites (37
• C for 30 min). For co-localization studies of matriptase with Dsg-2, CD44 or E-cadherin, fixed cells were stained with rabbit polyclonal anti-matriptase antibody (1:50 dilution in 1× PBS with 3 % BSA) and anti-Dsg-2 antibody [both the 6D8 and AH12.2 clones (1:50 dilution)], rat anti-CD44 (1:50 dilution) or mouse anti-E-cadherin (1:50 dilution) for 2 h at 37
• C. Secondary antibodies were diluted to 1:100 in 3 % BSA in 1× PBS and incubation was carried out for 1 h at room temperature. 
568-and E-cadherin Alexa Fluor
TM 568-conjugated goat anti-(mouse IgG) antibody (catalogue number A11004, Invitrogen) and CD44 Alexa Fluor TM 488-conjugated sheep anti-(rat IgG) antibody were used as secondary antibody conjugates. Individual controls for each primary antibody or the secondary antibodies were used. Each incubation step was followed by two washes with 1× PBS.
To visualize the nuclei and DNA, cells were stained with 1 μg/ml DAPI (4 ,6-diamidino-2-phenylindole) for 30 s at 37
• C followed by 1× PBS wash. All of the coverslips were mounted in PBS containing 50 % glycerol and 5 mM DABCO (1,4- 
Confocal images were obtained using the LSM (laser-scanning microscope) 510 Meta Carl Zeiss confocal system with Argon 488 nm and Helium/Neon 543 nm lasers. Images were acquired using Observer Z.1 microscope using a plan-apochromat ×63 oil objective lens with ×2 optical zoom. Processing of the acquired images, mean fluorescence intensity and overlap coefficient measurements were done using LSM software.
Hanging-drop assay
Cell counts were adjusted to 20 000 cells/μl in complete DMEM. They were suspended as 35-μl-sized drops from the lid of a well (24-well plates) and incubated for 16 h at 37
• C in 5 % CO 2 . PBS (1×) was used to maintain humidity. Post-incubation, each drop was mixed five times, fixed with 10 μl of 3 % glutaraldehyde and the aliquots (40 μl) were spread on autoclaved coverslips to be air dried [27] . Finally, the coverslips were mounted on to slides as described above. Images of five random fields for each sample were taken with a plan-Neofluar lens (numerical aperture = 0.3) at ×10 on an upright AxioImager Z1 microscope (Carl Zeiss). The area of cell clusters was determined using Axiovision rel 4.5 software (Zeiss).
Specific knockdown of matriptase using siRNA ON-TARGETplus smart pool siRNA for matriptase (catalogue number L-003712-00), SiGLO Green transfection indicator (catalogue number D-001630-01-05) siRNA and transfecting reagent (catalogue number T2001-63) and 5× siRNA buffer (catalogue number B-002000UB100) were purchased from Dharmacon Scientific. Freeze-dried siRNAs were reconstituted and diluted in the requisite buffers in DEPC (diethyl pyrocarbonate; catalogue number D-5758, Sigma)-treated autoclaved eppendorfs. siRNAs were reconstituted in 1× siRNA buffer and their integrity was confirmed by nanodrop spectrophotometer following the manufacturer's instructions. Further dilutions were carried out with 1× siRNA buffer to obtain 20 μM and 100 μM stocks which were further diluted to 50 nM for the reactions. Transfection efficiency of 77 % was observed by FACS in SiGLO-transfected HCT-116 wt cells. For optimal knockdown of matriptase, 30 000 HCT-116 wt cells/ml were seeded on to autoclaved coverslips or sterile 35-mm dishes. They were treated with 50 nM of matriptase siRNA in 2.5 μl/ml of transfection reagent. FITC-labelled siRNA served as the negative control. After a 24 h incubation, the medium was replaced by normal complete medium. Cells were allowed to proliferate for another 24 h and harvested for Western blotting, IF (immunofluorescence) or cell-adhesion assays.
Constructs, expression and purification of the active protease domain of matriptase
Matriptase cDNA in a pcDNA 3.1 vector was a gift from Dr ChenYong Lin (University of Maryland, Baltimore, MD, U.S.A.). The nucleotides corresponding to amino acids 596-855 (the autocatalytic and proteolytic domains of matriptase) were cloned using BamH1 and KpnI restriction enzymes with the forward (5 -GGATCCGGCTCAGATGAGAAGGACTGC-3 ) and reverse (5 -GGTACCTACCCCAGTGTTCTCTTTGAT-3 ) primers from Sigma. The PCR product was ligated to the pRSETA vector and transformed in Escherichia coli Rosetta strain cells. Expression was induced with 100 μM IPTG for 16 h at 24
• C. Bacterial cells were harvested, suspended in lysis buffer [50 mM Tris (pH 8.0), 500 mM NaCl, 10 % glycerol and 1 mM BME (2-mercaptoethanol)], sonicated (10 cycles of 1 cycle per min) and centrifuged at 20 000 rev./min (Sorval RC 5 rotor plus SS 34) for 30 min, the supernatant was collected and the pH was adjusted to 8. The catalytic domain of matriptase was purified using a Ni-NTA (Ni 2 + -nitrilotriacetate) affinity chelating column (catalogue number 30210, Qiagen) followed by size-exclusion chromatography (Superdex75, 16/60 column). Protein fractions were collected from 60 to 80 ml and samples were run on an SDS/PAGE gel (12 %). Fractions containing a single band at 27 kDa, corresponding to the molecular mass of matriptase, were pooled. Enzyme activity was monitored by incubating 120 μg β-casein with 0.25 μg/μl of purified recombinant matriptase in 200 μl of reaction mixture [100 mM Tris (pH 8.8) containing 0.5 μg/ml BSA]. β-Casein alone served as the control. Samples were incubated for 5 h and subjected to SDS/PAGE (15 % gel) analysis.
Cloning of Dsg-2 and creation of the R565A mutant
During processing and trafficking of Dsg-2 en route to the cell surface, signal and propeptide sequences (residues 1-50) will be cleaved. Therefore any tag at the N-terminus will have to be fused after the 50th amino acid. How this will affect folding, processing, transport and yield of Dsg-2 at the membrane surface is hard to predict. A tag at the C-terminus will not be reflective of proteolysis since it would protrude into the cytoplasm and may remain even after cleavage at the extracellular domain. Therefore we chose to overexpress the wt (cDNA of human Dsg-2 was a gift from Dr Werner Franke, German Cancer Research Center, Heidelberg, Germany) and mutant Dsg-2 in their native forms. We used the pCMV 3× FLAG vector for cloning (Invitrogen) for the following reasons: (i) we routinely use this vector in our laboratory for all mammalian protein expression; (ii) all of the proteins so far have exhibited excellent expression without alteration in localization or function; and (iii) no toxicity has been observed so far. wt Dsg-2 was cloned between NotI and BamHI restriction sites with the forward primer (5 -AATGTGCGGCCG-CGATGGCGCGGACGCGGGAC-3 ) and the reverse primer (5 -ATCGTCGGATCCTTAGGAGTAAGAATGCTGTA-3 ). When Dsg-2 is translated and processed, the FLAG tag will be removed and is unlikely to cause any problems associated with folding and trafficking. Site-directed mutagenesis (R565A within LGRS) was performed using PCR-based amplification with the forward primer (5 -GAAAAAGCTTGGGGCGAGTGAAATTCAGTT-3 ) and the reverse primer (5 -AACTGAATTTCACTCGCCCCA-AGCTTTTTCT-3 ).
Over-expression of wt and mutant Dsg-2 in HEK-293 cells
HEK-293 cells were seeded on to autoclaved coverslips and grown to 80 % confluence. They were transfected with any of the following: pCMV10 3× FLAG construct containing no gene, Dsg-2 wt or mutant Dsg-2 (R565A) using the calcium phosphate method. The cells were incubated for 48 h and treated with purified recombinant proteolytically active matriptase at 10 μg/ml and processed for IF as described above.
Statistical analysis
For each assay (where applicable) three independent experiments were performed. The P value for the intensity measurements was statistically analysed using an unpaired Student's t test and ANOVA (SPSS version 15 and Graphpad Prism). All of the statistical data were calculated from three independent experiments.
RESULTS
Predicted cleavage site KLGR∼SEIQ in the ectodomain of Dsg-2 is accessible to matriptase
Using our prediction program PNSAS we had identified Dsg-2 (from the proteome database) as one of the putative substrates of matriptase [1] . Both Dsg-2 and matriptase are cell-surface proteins. Dsg-2 is very important for cell adhesiveness and breaching of cell-cell contact is one of the early events in invasion and metastasis. Matriptase is an enzyme implicated in metastasis. Therefore we were curious to find if matriptase regulated the cell surface expression of Dsg-2 by cleaving it. If so, changes in the expression levels of active matriptase would reciprocally influence the surface levels of Dsg-2. Information from the UniProt-derived sequence of Dsg-2 (entry Q14126) is schematically represented to indicate the topological distribution and glycosylation sites of different regions of the protein (Figure 1a) . The matriptase cleavage site is indicated by the asterisk symbol. The P3P2P1∼P1 positions of the putative matriptase cleavage site in Dsg-2 are occupied by LGR∼S, with the scissile bond located between Arg 565 and Ser 566 . The molecular sizes of the expected cleavage fragments are also indicated (Figure 1a) . Since such a short sequence may be shared both by substrates and non-substrates of a protease, our program imposes filters to narrow down on the most probable physiologically relevant candidate substrates. One of the filters uses surface accessibility, which is computed from the high-resolution three-dimensional structure of the protein. There is no structure for Dsg-2 in the PDB. However, this protein belongs to the cadherin family (member 5) of proteins. The protein fold consists of four cadherin and six desmoglein repeats. The FASTA sequence of Dsg-2 was submitted to Modbase [28] . The most probable structure was built using the X-ray structure of c-cadherin ectodomain (PDB code 1L3W). The target sequence of amino acids 50-599 of Dsg-2 exhibited 34 % sequence identity with amino acids 2-540 of c-cadherin. The cleavage site LGR∼S (scissile bond between 565 and 566) is neither part of the desmoglein repeat or the cadherin domain. However, the region is nevertheless clearly modelled and could be overlaid with the corresponding region from c-cadherin (results not shown). We also independently modelled the structure of Dsg-2 using homology modelling against known structures in the PDB. Mouse N-cadherin ectodomain (PDB code 3Q2W) with 34 % identity in the region of amino acids 51-601 and a low DOPE (discrete optimized protein energy) score was modelled using Modeller [29] and the structure was verified using a Ramachandran plot. It is clear from Figure 1 (b) that the LGR∼S region is in a solvent-exposed part of the modelled protein and the putative cleavage site is likely to be well accessible to the protease. The SASA (solvent-accessible surface area) value of the octapeptide KLGR∼SEIQ (amino acids 562-569) harbouring the putative cleavage site between amino acids 565 and 566 was calculated using Surface Racer 5 [30] . This value can be compared with a known and easily accessible protease cleavage site in α-antitrypsin (AAGA∼MFLE; PDB code 1QLP; SASA value = 811.6) which is cleaved by matrix metallopeptidase 7 to obtain the rSASA (relative SASA) value, a quantitative index of accessibility. We had used this protein earlier as the reference point for calculating rSASA values of substrates [1] . Using this reference, the rSASA value for the Dsg-2 cleavage site will be 0.78, indicating that the site must be readily accessible to matriptase.
Co-localization of matriptase and Dsg-2 in HCT-116 wt cells
In order for an enzyme to act on its substrate, both should be found in the same subcellular compartment. Therefore the second filter that is imposed by PNSAS is subcellular distribution. Both matriptase and its candidate substrate Dsg-2 are transmembrane proteins. To ascertain the presence of these two proteins at the membrane surface and to analyse the extent to which they co-localize in HCT-116 wt cells, a double immunostaining was performed. The anti-matriptase antibody that we chose exclusively recognizes an epitope in the extracellular domain spanning amino acids 615-822. The monoclonal anti-Dsg-2 (clone 6D8) antibody recognizes an epitope in the extracellular domain of Dsg-2 harbouring the predicted cleavage site. Using these antibodies for immunostaining we found that matriptase and Dsg-2 are present on the surface of HCT cells with an overlap coefficient of 0.9, indicating that 90 % of matriptase and Dsg-2 are close to each other (Figures 2a and 2b , and Table 1 ). Western blotting of the subcellular fractions of HCT-116 wt cells with the same matriptase-specific antibody and AH12.2 clone for Dsg-2 revealed two immunoreactive bands, in the membrane fractions of the cells. They correspond to ∼ 80 kDa for matriptase and ∼ 130 kDa in the case of Dsg2 (Figure 2c ).
siRNA-mediated down-regulation of matriptase in HCT-116 wt cells results in more immunoreactive Dsg-2 at the cell surface
In order to demonstrate that Dsg-2 is a candidate substrate for matriptase in the cellular context, we used siRNA to down-regulate the enzyme in HCT-116 wt cells. If Dsg-2 was a substrate for matriptase then upon depletion of the enzyme the levels of immunoreactive Dsg-2 should increase. The antibody we chose is established to interact with the extracellular domain harbouring the cleavage site. After 48 h of siRNA treatment, Western blotting showed a 95 % decrease in the band intensity of matriptase confirming knock-down (Figure 3a) . Parallel IF studies showed that the intensity of matriptase signal in siRNA-treated cells was diminished by 61 % (P = 0.023) with a concomitant 55 % increase in the intensity of Dsg-2 (P = 0.022) (Figure 3b and Supplementary Figure  S1 at http://www.BiochemJ.org/bj/447/bj4470061add.htm). To verify that the up-regulation of Dsg-2 on the cell surface was a specific response to matriptase down-regulation, we checked levels of two other surface proteins, CD44 and E-cadherin, in the knock-down cells. Among these two proteins, CD44 carries a potential cleavage site, QART, whereas E-cadherin lacks any known cleavage site for matriptase. We observed no measurable differences in the levels of CD44 (Supplementary Figure S2 at http://www.BiochemJ.org/bj/447/bj4470061add.htm) and Ecadherin (Supplementary Figure S3 at http://www.BiochemJ. org/bj/447/bj4470061add.htm) between control and siRNAtreated HCT-116 wt cells. The lack of cleavage of CD44 harbouring a putative cleavage site for matriptase is probably due to its inaccessibility or requirement for additional levels of regulation. We could not model the structure of CD44 due to a lack of appropriate templates. It seems that cleavage of Dsg-2 by matriptase is a specific and well-regulated process in the context of a cell.
Matriptase down-regulated cells form bigger cell clusters owing to increased levels of Dsg-2
Dsg-2 is a key desmosomal protein involved in maintaining cellcell contact via homophilic and heterophilic interactions with other desmosomal proteins of adjacent cells. Increase in the levels of Dsg-2 at the cell surface is expected to increase cell adhesiveness. If cleavage of Dsg-2 by matriptase was functionally relevant then one may expect increase in cell-cell contact in matriptase knock-down cells mediated by Dsg-2. To test this possibility a hanging-drop assay was performed [27] . As expected, the cells treated with siRNA for matriptase formed bigger clusters (152.1 + − 38.3 μm) when compared with the control cells (21.7 + − 3.0 μm) (Figure 4 ). This indicates that activity of matriptase is an important regulator of cell-cell adhesion via Dsg-2 and this reciprocal relationship between the levels of matriptase and Dsg-2 could be one of the parameters that determine cell invasiveness.
Exogenously added pure active recombinant matriptase decreases the levels of immunoreactive Dsg-2 on the cell surface of HCT-116 wt cells
To prove further that matriptase alters levels of Dsg-2 at the cell surface by cleaving it, a recombinant matriptase corresponding to amino acids 596-855 was expressed, isolated and purified.
A single band at 27 kDa corresponding to the molecular mass of recombinant matriptase was observed (Figure 5a ). This was confirmed to be matriptase by Western blotting (results not shown). Purified matriptase was able to hydrolyse β-casein, an unstructured protein used routinely to monitor the in vitro activity of endoproteases. Following a 5 h incubation with matriptase, distinct fragments of β-casein corresponding to ∼ 17 kDa, 12 kDa, 11 kDa and 9 kDa were observed only in the presence of recombinant matriptase (Figure 5b ). HCT-116 wt cells were then incubated with this proteolyticaly active pure recombinant matriptase at 5 and 10 μg/ml concentrations for 2 h and were processed for immunostaining. There was a marked reduction in the immunostaining of Dsg-2 in the matriptase-treated cells. The mean fluorescence intensity of Dsg-2 in the cells treated with 5 and 10 μg/ml of matriptase was 55.7 % (P = 0.006) and 34.1 % (P = 0.032) respectively as compared with their untreated counterparts ( Figure 6 ). Unlike Dsg-2, no effect was seen in the intensity of CD44 and Ecadherin (Supplementary Figure S4 at http://www.BiochemJ. org/bj/447/bj4470061add.htm) levels. The cells without any matriptase at pH 7.5 and at 8.8 (optimum pH for matriptase activity) had comparable intensity values for Dsg-2 (Figure 6a) , thereby confirming that pH itself did not induce any change in Dsg-2 expression. In both the control and the treated samples the cells displayed fillopodial projections, which may be due to serum starvation.
Mobilization of intracellular pools of matriptase to cell surface by S1P decreased surface levels of Dsg-2
Previous studies have reported that S1P caused accumulation and activation of matriptase at mammary epithelial cellcell contacts [2] [3] [4] . In order to further establish specific cleavage of Dsg-2 by endogenous matriptase, we stimulated HCT-116 wt cells with S1P. Subsequent to treatment with S1P, there was a time-dependent progressive increase in the levels of matriptase [48.7 % increase after a 2 h incubation (P = 0.01)]. There was a corresponding decrease in immunoreactive Dsg-2 amounting to a 40.3 % (P = 0.017) loss in intensity (Figures 7a and 7b , and Supplementary Figure S5 at http://www.BiochemJ.org/bj/447/bj4470061add.htm). Under the same conditions, the intensity values of Dsg-2 and matriptase in untreated cells remained essentially unaltered. These results confirm the reciprocal relationship between endogenous matriptase and Dsg-2, which reiterates that Dsg-2 is a physiologically relevant substrate of matriptase.
To facilitate the identification of the cleaved products, the cell lysates and concentrated conditioned media of the control and S1P-treated HCT-116 cells were immunoblotted. A distinct decrease in the band intensity of Dsg-2 in the whole-cell lysates was accompanied by concomitant appearance of a ∼ 80 kDa fragment in the conditioned medium of both the samples (Figure 7c ). In correlation with the presence of more active matriptase at the cell surface, the 80 kDa band in the S1P-treated cells exceeded that of the control cells. On the basis of previous reports, we envisaged that this fragment could be the shed ectodomain of Dsg-2 [25] . Appearance of the 80 kDa fragment in the control cells is probably due to the normal ongoing cleavage of Dsg-2 at the cell surface by matriptase which is further augmented by S1P treatment. Some amount of this product could be due to ongoing apoptosis-like mechanisms, which might contribute to anikoisis or detachment of cells from the surface via cleavage of adhesion-promoting proteins like Dsg-2.
In order to verify the identity of the cleaved products, the UniProt sequence of Dsg-2 was submitted to Expasy Protparam (http://www.expasy.org/tools/protparam.html) [31] and the theoretical molecular masses of the expected fragments were calculated. After removing both the pro and signal peptide sequences, the molecular mass of Dsg2 was calculated to be 116 kDa. However, an immune reactive product at 130 kDa was consistently detected upon Western blotting of the membrane fraction, indicating that this is probably the glycosylated form of Dsg-2. If matriptase cleaved at the predicted site within Dsg-2 (LGR∼S) it would generate two fragments: a 50-565 amino acid fragment of ∼ 57 kDa (57661.9), which would harbour the epitope for the AH12.2 antibody [32] , and a 566-1119 amino acid fragment of ∼ 59 kDa (59020.3) (Figure 1a) . Consistent with this estimate, Coomassie Blue staining of the S1P-treated conditioned media revealed a product at ∼ 58-60 kDa (Figure 7d ) which was not immune reactive and an immune reactive band at a higher molecular mass of ∼ 80 kDa. This fragment with an aberrant molecular mass may originate from the epitope harbouring amino acids 50-565 and is probably glycosylated like the parent protein.
Matriptase cleaves Dsg-2 at the scissile bond within LGR∼S
So far all of the results show that matriptase cleaves endogenous Dsg-2 and the cleavage most likely occurs within LGR (P1)∼S (P1 ). In order to unequivocally establish the specific cleavage site, it will be important to show that mutation at the predicted site in Dsg-2 prevents cleavage by matriptase. We decided to overexpress the wt and mutant Dsg-2 carrying a point mutation at Arg 565 (R565A) and incubate them with purified matriptase. HEK-293 cells were transfected with the wt and mutant Dsg-2 (R565A) under the constitutive promoter CMV (cytomegalovirus). To confirm overexpression, at 48 h posttransfection the cells were harvested for Western blotting (Figure 8a ) or were immunostained. Both Western blotting-and IF-based mean fluorescence intensity measurement confirmed >1.8-fold overexpression of Dsg-2 in the wt and mutant populations. Transfected cells were incubated with 10 μg/ml of proteolytically active recombinant matriptase, as described above. There was a marked reduction in the immunostaining of Dsg-2 in the cells treated with matriptase. The mean fluorescence intensity of Dsg-2 in matriptase-treated untransfected cells was 44.9 % (P < 0.0001), in cells overexpressing wt Dsg-2 28.5 % (P < 0.0001) and in cells overexpressing mutant Dsg-2 it was 75.6 % (P < 0.0001) as compared with their respective untreated counterparts (Figure 8b) .
The 25 % loss in Dsg-2 intensity in the mutant cells is probably due to matriptase-mediated degradation of the endogenous Dsg-2 rather than proteolysis of mutant Dsg-2. Hence we can safely conclude that the inability of matriptase to cleave mutant Dsg-2 could be due to the absence of Arg 565 at the P1 position of the scissile bond in the LGR∼S sequence that is recognized and cleaved by matriptase. To eliminate observer bias, wider fields (152 μm×152 μm) accommodating a greater number of cells were randomly chosen and acquired as 'tile images' using Zen software. Similar differences in Dsg-2 immunostaining between matriptase-treated and untreated wt or mutant overexpressing cells were observed (results not shown). This corroborates our above results that the mutation affected the ability of matriptase to cleave Dsg-2 at the predicted site.
Our repeated attempts to recapitulate the IF results by Western blotting were unsuccessful. We assume that, in light of excessive expression of wt and mutant Dsg-2 by the cells, 10 μg/ml of matriptase may be insufficient to bring about the significant proteolysis that could be detected in cell lysates. Cells treated with matriptase exceeding 10 μg/ml underwent rapid and progressive detachment from the coverslips. To avoid compromising the cells' viability, we decided to use 10 μg/ml matriptase and employ IF to simultaneously visualize and reliably quantify the subtle changes in the Dsg-2 expression levels in response to matriptase.
DISCUSSION
We had previously proposed a method, called PNSAS, to predict putative substrates of endoproteases with the hope that it will be a useful complementary approach in the current day attempts towards global profiling of proteases and their substrates [1] . The power of this method lies in the use of short peptide motifs which on one hand are big enough to provide specificity and on the other are small enough to cover a broad spectrum of proteins. In addition our method uses physiologically relevant filters, namely accessibility in terms of the folded structure of a protein and subcellular localization. We chose to test the ability of matriptase to cleave Dsg-2, a surface membrane protein important for cell adhesion. Breaching of cell-cell contact is an important event in the process of invasion and metastasis.
By a systematic study we have clearly demonstrated that matriptase regulates steady state levels of Dsg-2. To do so we have used: (i) pure active recombinant matriptase added exogenously to cleave Dsg-2 at cell surface and (ii) altered the endogenous surface levels of active matriptase by either down-regulating its expression or by mobilizing it from subcellular deposits. By combining IF and Western blot analysis to monitor the levels of Dsg-2 under these different conditions, we show that a decrease in levels of Dsg-2 is accompanied by what seems to be a cleaved product in the conditioned medium of treated cells. We were able to demonstrate the specificity of this cleavage process using CD44 and E-cadherin, levels of which were unaffected. In addition we overexpressed a mutant Dsg-2 (R565A) in which the predicted cleavage site at P1, Arg 565 , was mutated to an alanine residue. Upon the addition of exogenous purified matriptase, HEK-293 cells expressing mutant Dsg-2 retained significantly higher levels of the immunopositive Dsg-2 as compared with the cells expressing wt Dsg-2 or the untransfected cells. These experiments taken together provide strong evidence that Dsg-2 is cleaved by matriptase at the predicted site. Our modelled structure shows that this is a distinct possibility since the predicted site is in a well-accessible region. The presence of Dsg-2 with an intact extracellular domain at the cell surface when matriptase was down-regulated resulted in increased cell-cell contact and adhesiveness.
Matriptase, as described in the Introduction section, is overexpressed in many solid tumours of epithelial origin and is implicated in cell invasion and metastasis. However, the mechanism by which matriptase can achieve these remains unclear. By demonstrating the ability of matriptase to regulate the levels of Dsg-2, we provide a plausible rationale for the role of matriptase in cell invasion and metastasis. Similar to our cellbased studies, when the levels of matriptase increase then Dsg-2 is likely to be cleaved more in tumour tissues by matriptase. This would provide a gain of function phenotype by which cells would increase their motility by breaking cell-cell contact, creating an environment conducible for invasion and metastasis. Whether a similar inverse correlation in the levels of Dsg-2 and matriptase exits in cells of solid tumours and whether they are responsible for invasive properties remains to be seen. Since cell invasive properties are controlled by many factors, it will be difficult to establish a direct correlation between the two phenomena. Nevertheless our results suggest that such a strong possibility exists and provides proof of principle that our prediction program is likely to get integrated in global profiling studies of in vivo substrates of endoproteases.
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